Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
122.28(c) 124.58(c) 133.99(c) 135.63(c) 136.28(c) Last
1 431 567 2 028 594 2 893 166 1 731 406 1 640 863 Volume
+3.58% +1.88% +7.55% +1.22% +0.48% Change
More quotes
Financials ($)
Sales 2017 1 427 M
EBIT 2017 -61,4 M
Net income 2017 -135 M
Finance 2017 268 M
Yield 2017 -
Sales 2018 1 624 M
EBIT 2018 146 M
Net income 2018 93,6 M
Finance 2018 668 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 326,19
EV / Sales2017 19,3x
EV / Sales2018 16,7x
Capitalization 27 774 M
More Financials
Company
Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology.Its product, Jakafi, a JAK1 and JAK2 inhibitor, is... 
More about the company
Surperformance© ratings of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INCYTE CORPORATION
06/22 ELI LILLY AND : New Safety and Long-Term Efficacy Data from Baricitinib Clinical..
06/20 INCYTE : Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arth..
06/20 INCYTE : New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials..
06/16 INCYTE : New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials..
06/15 INCYTE : Analyst and Investor Event to Highlight Clinical Data Presentations fro..
06/15 INCYTE : Updated Data from ECHO-202 Trial of Incyte's Epacadostat in Combination..
06/14 INCYTE : Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arth..
06/09 INCYTE : Researchers at Incyte Corporation Report New Data on Medicinal Chemistr..
06/07 INCYTE : to Present at Upcoming Investor Conferences
06/06 INCYTE CORPORATION : Corporate News Blog - Incyte and Merck Release Phase-1/2 Cl..
More news
Sector news : Biotechnology & Medical Research - NEC
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
06/22Eventide Asset Management LLC Has $5,347,000 Position in Incyte Corporation $.. 
06/22Incyte Corporation $INCY Stake Decreased by Nippon Life Global Investors Amer.. 
06/22Amgen : Today's Research Reports on Stocks to Watch: Amgen and Incyte  
06/22$INCY THEY ROLLED INTO SEP'S LAST MONTH AFTER SCORE. HAD NICE RAMP AGAIN, PU..
4
06/21Edmond DE Rothschild Holding S.A. Has $12.03 Million Position in Incyte Corpo.. 
More tweets
Qtime:52
News from SeekingAlpha
06/21 Biotech's Best Chance Has Gotten Even Better
06/16 Incyte Corporation (INCY) Presents At Nasdaq 36th Investor Program - Slidesho..
06/15 Incyte (INCY) Presents At Goldman Sachs 38th Annual Global Healthcare Confere..
06/15 Incyte (INCY) Presents At The William Blair 2017 Growth Stock Conference - Sl..
06/14 Don't Sell Domino's - Cramer's Lightning Round (6/13/17)
Advertisement
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 147 $
Spread / Average Target 8,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Senior Vice President
Paul Alan Brooke Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION33.63%27 774
QUINTILES IMS HOLDINGS..19.50%19 614
LONZA GROUP26.33%15 927
CELLTRION, INC.--.--%12 175
SEATTLE GENETICS, INC.19.86%9 027
ALKERMES PLC5.58%8 989
More Results